Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENTX Entera Bio	$1.95 +2.6%	$1.94	$1.50 ▼ $2.79	$86.76M	1.52	293,228 shs	14,027 shs
EXOZ eXoZymes	$9.31 -4.8%	$10.14	$8.50 ▼ $23.99	$82.07M	N/A	3,258 shs	7,776 shs
IGMS IGM Biosciences	$1.27	$1.27	$0.92 ▼ $22.50	$76.57M	0.6	480,746 shs	N/A
RVPH Reviva Pharmaceuticals	$0.52 +0.2%	$0.48	$0.30 ▼ $4.28	$24.92M	-0.05	2.79 million shs	1.49 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENTX Entera Bio	+0.53%	-2.06%	-4.52%	-3.50%	+13.77%
EXOZ eXoZymes	0.00%	-2.10%	+3.38%	-33.01%	+977,999,900.00%
IGMS IGM Biosciences	0.00%	0.00%	-0.78%	+5.83%	-87.22%
RVPH Reviva Pharmaceuticals	-2.74%	+12.87%	+31.34%	-50.55%	-54.46%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ENTX Entera Bio	1.1341 of 5 stars	2.0	3.0	0.0	0.0	2.8	0.8	0.0
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
IGMS IGM Biosciences	4.503 of 5 stars	3.0	3.0	0.0	4.6	3.0	3.3	1.3
RVPH Reviva Pharmaceuticals	2.8399 of 5 stars	3.6	1.0	0.0	0.0	2.9	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENTX Entera Bio	4.00	Strong Buy	$10.00	412.82% Upside
EXOZ eXoZymes	0.00	N/A	N/A	N/A
IGMS IGM Biosciences	1.90	Reduce	$5.50	333.07% Upside
RVPH Reviva Pharmaceuticals	3.13	Buy	$7.17	1,278.21% Upside

Current Analyst Ratings Breakdown

Latest RVPH, EXOZ, ENTX, and IGMS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	RVPH Reviva Pharmaceuticals	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $3.00
8/18/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
8/15/2025	RVPH Reviva Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/15/2025	RVPH Reviva Pharmaceuticals	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $2.00
8/11/2025	ENTX Entera Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/27/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
6/3/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00

(Data available from 8/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENTX Entera Bio	$180K	494.65	N/A	N/A	$0.38 per share	5.13
EXOZ eXoZymes	$70K	1,115.87	N/A	N/A	$0.86 per share	10.83
IGMS IGM Biosciences	$145.05M	0.53	N/A	N/A	$1.67 per share	0.76
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	($0.01) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENTX Entera Bio	-$9.54M	-$0.26	N/A	N/A	N/A	-4,525.11%	-77.75%	-68.13%	N/A
EXOZ eXoZymes	-$5.86M	N/A	0.00	∞	N/A	N/A	-134.50%	-81.63%	N/A
IGMS IGM Biosciences	-$195.79M	-$0.90	N/A	N/A	N/A	-36.81%	-93.35%	-24.15%	N/A
RVPH Reviva Pharmaceuticals	-$29.92M	-$0.65	N/A	N/A	N/A	N/A	N/A	-259.17%	N/A

Latest RVPH, EXOZ, ENTX, and IGMS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	RVPH Reviva Pharmaceuticals	-$0.15	-$0.12	+$0.03	-$0.12	N/A	N/A
8/12/2025	Q2 2025	EXOZ eXoZymes	N/A	-$0.28	N/A	-$0.28	N/A	N/A
8/8/2025	Q2 2025	ENTX Entera Bio	-$0.11	-$0.06	+$0.05	-$0.06	N/A	N/A
7/31/2025	Q2 2025	IGMS IGM Biosciences	-$0.30	$1.58	+$1.88	$1.58	$3.20 million	$143.62 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
EXOZ eXoZymes	N/A	N/A	N/A	N/A	N/A
IGMS IGM Biosciences	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENTX Entera Bio	N/A	10.47	10.47
EXOZ eXoZymes	0.01	6.19	6.19
IGMS IGM Biosciences	N/A	17.66	17.66
RVPH Reviva Pharmaceuticals	N/A	0.90	0.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENTX Entera Bio	14.11%
EXOZ eXoZymes	N/A
IGMS IGM Biosciences	42.79%
RVPH Reviva Pharmaceuticals	63.18%

Insider Ownership

Company	Insider Ownership
ENTX Entera Bio	10.38%
EXOZ eXoZymes	72.41%
IGMS IGM Biosciences	57.00%
RVPH Reviva Pharmaceuticals	27.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENTX Entera Bio	20	45.66 million	40.92 million	Optionable
EXOZ eXoZymes	29	8.39 million	2.31 million	N/A
IGMS IGM Biosciences	190	60.29 million	25.93 million	Optionable
RVPH Reviva Pharmaceuticals	5	48.00 million	34.96 million	Optionable

RVPH, EXOZ, ENTX, and IGMS Headlines

Recent News About These Companies

Reviva Pharmaceuticals (NASDAQ:RVPH) Receives "Buy" Rating from D. Boral Capital

August 20 at 2:19 AM | americanbankingnews.com

RVPH: There May Be A Faster Way

August 19 at 7:56 PM | finance.yahoo.com

Reviva Pharmaceuticals Advances Schizophrenia Treatment

August 18 at 12:30 AM | tipranks.com

Maxim Group Cuts Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target to $2.00

August 18 at 2:06 AM | americanbankingnews.com

Reviva Pharmaceuticals price target lowered to $3 from $7 at Roth Capital

August 18 at 2:33 AM | msn.com

Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Rating Upgraded by Wall Street Zen

August 16, 2025 | americanbankingnews.com

Reviva Narrows Loss 23% in Fiscal Q2

August 14, 2025 | aol.comA

Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights

August 14, 2025 | globenewswire.com

Reviva Pharmaceuticals (RVPH) Expected to Announce Quarterly Earnings on Wednesday

August 12, 2025 | americanbankingnews.com

Reviva Pharmaceuticals Holdings, Inc. (RVPHW) - Yahoo Finance

July 5, 2025 | finance.yahoo.com

Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Investing.com

June 29, 2025 | investing.com

Reviva Dives on Stock Offering

June 26, 2025 | baystreet.ca

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

June 26, 2025 | globenewswire.com

Reviva Pharmaceuticals stock falls after announcing public offering

June 25, 2025 | za.investing.com

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

June 25, 2025 | globenewswire.com

RVPH: Open Label Extension Results & Key Opinion Leader Discussion

June 5, 2025 | finance.yahoo.com

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 5, 2025 | globenewswire.com

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

June 2, 2025 | globenewswire.com

Reviva to Participate in Upcoming Investor Conferences in May 2025

May 20, 2025 | santelog.comS

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

RVPH, EXOZ, ENTX, and IGMS Company Descriptions

Entera Bio NASDAQ:ENTX

$1.95 +0.05 (+2.63%)

Closing price 04:00 PM Eastern

Extended Trading

$1.92 -0.03 (-1.54%)

As of 07:27 PM Eastern

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

eXoZymes NASDAQ:EXOZ

$9.31 -0.47 (-4.81%)

As of 04:00 PM Eastern

eXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV.

IGM Biosciences NASDAQ:IGMS

$1.27 0.00 (0.00%)

As of 08/14/2025

IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.

Reviva Pharmaceuticals NASDAQ:RVPH

$0.52 +0.00 (+0.15%)

Closing price 04:00 PM Eastern

Extended Trading

$0.52 0.00 (0.00%)

As of 07:41 PM Eastern

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time